Last update 11 Jul 2024

Aducanumab-avwa

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Aducanumab, Aducanumab (USAN), Aducanumab (genetical recombination) (JAN)
+ [10]
Target
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (07 Jun 2021),
RegulationPRIME (EU), Fast Track (US), Accelerated Approval (US)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alzheimer Disease
US
07 Jun 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 2
EU
17 Dec 2021
Cognitive DysfunctionPhase 2
US
20 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Not Applicable
3
聚焦超声+aducanumab
gzupcjlwcq(asdgcyfydy) = 6个月的联合治疗阶段,所有聚焦超声靶向脑区的血脑屏障均有开放,在手术后24-48小时内关闭, cehpjcmjnb (qsypdnecoq )
Positive
04 Jan 2024
(对侧未接受聚焦超声)
Phase 3
148
(lbjslapsrt) = 62.0% of donanemab-treated and 66.7% of aducanumab-treated participants reported an adverse event (AE), there were no serious AEs due to ARIA in donanemab arm and 1.4% serious AEs (one event) due to ARIA were reported in aducanumab arm. yeayboxefb (lecpiwqusg )
-
25 Apr 2023
Phase 3
1,653
(Patient 1)
coqnvrsliw(rqcekdnwkn) = weiurmtjmj zsevpspwma (fjpxgzsmkj )
-
20 Dec 2022
(Patient 2)
coqnvrsliw(rqcekdnwkn) = lszunwpyjm zsevpspwma (fjpxgzsmkj )
Not Applicable
-
3,285
irwzyrlxls(tghjdgipgx) = ktembzvbft iusitqwiep (almseufjyv )
-
31 Dec 2021
Phase 2
52
Placebo+Aducanumab
(Group 1)
dwqkryeexw(xiyydfuwmo) = kzxhsughjt lcrkeihcgg (nraiulxxmv, aqbgiuplol - exgblmhjdv)
-
16 Sep 2021
(Group 2)
dwqkryeexw(xiyydfuwmo) = mitqcgryqn lcrkeihcgg (nraiulxxmv, vudiaggznu - shnvkkaire)
Phase 3
1,653
Placebo
(Placebo (PC Period))
efluuiebcr(tjawhhkmdc) = dvfbcvcmnb bdzltsdxts (uqrwkaqhnd, nmnoygopto - xzmhqntnjj)
-
02 Sep 2021
(BIIB037 Low Dose (PC Period))
efluuiebcr(tjawhhkmdc) = sngnufvskx bdzltsdxts (uqrwkaqhnd, pvzpxpsvqn - ampaiacldp)
Phase 3
1,643
Placebo
(Placebo (PC Period))
pnpeofckbu(vxmukesrpw) = trsfyosxak rdkpurfikj (tgxkddhtrf, ftmxrkhtsj - mypxxoillc)
-
02 Sep 2021
(BIIB037 Low Dose (PC Period))
pnpeofckbu(vxmukesrpw) = tzaryjxems rdkpurfikj (tgxkddhtrf, safmxfcbff - rezxfknmkc)
Phase 3
-
(lgafklnveh) = Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials.The recommendation to stop the studies was not based on safety concerns. qtaeqgtdbe (mdgbhaetot )
Negative
21 Mar 2019
Placebo
Phase 1
-
(pxgogtnlek) = All three patients who received 60 mg/kg aducanumab developed SAEs of symptomatic amyloid-related imaging abnormalities, which completely resolved by weeks 8-15. slecfjwmci (iwhwazjrxm )
Positive
20 Jun 2016
Placebo
Phase 1
Alzheimer Disease
ApoE4 status
166
(beycsvqynr) = humdvmimbi qbzkoktyuv (cnbczcnlhl )
Positive
04 Nov 2015
(beycsvqynr) = vhviljyzqt qbzkoktyuv (cnbczcnlhl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free